| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/31/2001 | CA2394914A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2393322A1 Method of proliferating natural killer cells |
| 05/31/2001 | CA2393126A1 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 05/31/2001 | CA2392495A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392400A1 A human normal counterpart of cd4+ cd56+ cutaneous neoplasm |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392351A1 Novel transcription factor and dna thereof |
| 05/31/2001 | CA2392272A1 Modified adenovirus fibre and uses |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2391922A1 Excipient system that contains coating substances with enzymatically removable side-groups |
| 05/31/2001 | CA2391526A1 A pharmaceutical composition for treatment of diseases associated with decrease in bone mass |
| 05/31/2001 | CA2391434A1 Anti-angiogenic cellular agent for cancer therapy |
| 05/31/2001 | CA2391386A1 Peptides having antiangiogenic activity |
| 05/31/2001 | CA2391012A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2390802A1 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 05/31/2001 | CA2390465A1 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2389667A1 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| 05/31/2001 | CA2389537A1 Mixture of pomegranate seed oil and juice products |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/31/2001 | CA2386955A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/31/2001 | CA2386893A1 N-alkylated peptides having antiangiogenic activity |
| 05/30/2001 | EP1103623A1 Human mucin core protein: nucleic acid probes, peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods |
| 05/30/2001 | EP1103615A1 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| 05/30/2001 | EP1103607A1 Enhancement of tmTNF levels for the sensitisation of tumours to sTNF and/or cytostatic drugs |
| 05/30/2001 | EP1103602A1 New lymphocytes, a process for preparing the same and their use, in therapeutics |
| 05/30/2001 | EP1103554A1 Derivatives of dihydrofuro-(3,4-b)-quinolein-1-ones, process of préparation and phamaceutical compositions containing them |
| 05/30/2001 | EP1103272A2 Modulation of TGF-beta by proteolytic enzymes |
| 05/30/2001 | EP1103268A1 Use of staphylococcal enterotoxins or related compounds for cancer treatment by infusion |
| 05/30/2001 | EP1103266A2 Formulations of curcumine |
| 05/30/2001 | EP1103265A1 T-cells specific for polymorphic proteins on malignant cells |
| 05/30/2001 | EP1103263A2 Poly-L-lactates as antitumour agents |
| 05/30/2001 | EP1102862A1 Antisense oligonucleotides targeted to il-15 |
| 05/30/2001 | EP1102855A1 Method for producing plants with increased flavonoid and phenolic compound content |
| 05/30/2001 | EP1102853A1 N-acetylglycosaminyltransferase genes |
| 05/30/2001 | EP1102848A2 Molecules designated ldcam |
| 05/30/2001 | EP1102842A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102776A1 Water soluble prodrugs of hindered alcohols or phenols |
| 05/30/2001 | EP1102775A1 Novel phospholipids with unsaturated alkyl and acyl chains |
| 05/30/2001 | EP1102758A1 Particle-forming compositions containing fused pyrrolocarbazoles |
| 05/30/2001 | EP1102753A2 Pyrazoles as estrogen receptor modulators |
| 05/30/2001 | EP1102746A1 Substituted phenylamidines with antithrombotic action |
| 05/30/2001 | EP1102604A1 Drug releasing elastic band and method |
| 05/30/2001 | EP1102596A1 Peptide antagonists of zonulin and methods for use of the same |
| 05/30/2001 | EP1102594A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 05/30/2001 | EP1102587A2 Vitronectin receptor antagonists |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP1102582A2 Inhibitors of type 3 3alpha-hydroxysteroid dehydrogenase |
| 05/30/2001 | EP0914334B1 Process and intermediates for the synthesis of lhrh antagonists |
| 05/30/2001 | EP0886654B1 Thioureido-cyclodextrins particularly useful for solubilising antitumoral and antiparasitic agents, and methods for preparing same |
| 05/30/2001 | EP0730607B1 Novel integrin-binding peptides |
| 05/30/2001 | EP0660712B1 Transcutaneous in vivo activation of photosensitive agents in blood |
| 05/30/2001 | CN1297531A Isolated nucleic acid molecule encoding cancer associated antigens, antigens per se, and uses thereof |
| 05/30/2001 | CN1297479A Modified adenovirus contg. fiber replacement protein |
| 05/30/2001 | CN1297442A 5-aminoindeno [1,2-c] pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 05/30/2001 | CN1297438A Substd. indolinones having inhibiting effect on kinases and cycline/CDK complexes |
| 05/30/2001 | CN1297436A Substd. pyrrolidine hydroxamate metalloprotease inhibitors |
| 05/30/2001 | CN1297350A Agents for relieving side effects |
| 05/30/2001 | CN1297051A Polypeptide-human phosphatase 79 and polynucleotide for coding said polypeptide |
| 05/30/2001 | CN1296975A Polypeptide-human ribosomal protein L23 and polynucleotide for coding said polypeptide |
| 05/30/2001 | CN1296826A Medicine for treating mastopathy |
| 05/30/2001 | CN1296823A Antineoplastic Chinese medicine and its preparing process |
| 05/30/2001 | CN1296818A Anti-malignant tumor agent for malignant neoplasm contg. cancer |
| 05/30/2001 | CN1066456C Oligonucleotides having 2'-ether groups |
| 05/30/2001 | CN1066446C 4-amino-3-acylnaphthyridine derivs. |
| 05/30/2001 | CA2327026A1 Quinoline derivatives useful for inhibiting farnesyl protein transferase |
| 05/29/2001 | US6239288 Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis |
| 05/29/2001 | US6239284 Skin disorders; anticancer agents |
| 05/29/2001 | US6239259 Multivalent and multispecific antigen-binding protein |
| 05/29/2001 | US6239257 Family of proteins belonging to the pancreatic ribonuclease a superfamily |
| 05/29/2001 | US6239256 Isolated muteins of proteins SCP-1, and compositions containing the mutein |
| 05/29/2001 | US6239181 Method for preventing and treating peripheral neurophathy by administering selegiline |
| 05/29/2001 | US6239176 Administering to treat blood disorders like anemia; wound healing, anticarcinogenic and antiproliferative agents; genetic disorders |
| 05/29/2001 | US6239173 Antiinflammatory, antipyretic, analgesic, and antiarthritic agents |
| 05/29/2001 | US6239171 Tocotrienols and tocotrienol-like compounds and methods for their use |
| 05/29/2001 | US6239167 Antitumor compositions containing taxane derivatives |
| 05/29/2001 | US6239161 Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions |
| 05/29/2001 | US6239151 Compounds as inhibitor of tumor necrosis factor alpha release |
| 05/29/2001 | US6239137 Salts of aminoimidazole carboxamide and 5 amino or substituted amino 1,2,3-triazole, induce apoptosis, inhibit DNA synthesis and control cyclooxygenase activity |
| 05/29/2001 | US6239127 Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation |
| 05/29/2001 | US6239116 Immunostimulatory nucleic acid molecules |
| 05/29/2001 | US6239114 Triterpene derivatives, antitumor |
| 05/29/2001 | US6239104 Isolated and purified substance which inhibits neoplastic cell growth denominated dolastatin 16 |
| 05/29/2001 | US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol |
| 05/29/2001 | US6238921 Antisense oligonucleotide modulation of human mdm2 expression |
| 05/29/2001 | US6238881 Nucleotide sequence which codes for p115 rho-guanine exchange factor involved in cell signalling; therapeutics; diagnostics; recombinant culture production; antibodies; probes |
| 05/29/2001 | US6238878 FVlla/TF activity inhibiting compounds |
| 05/29/2001 | US6238668 Administering polysaccharide |
| 05/29/2001 | US6238666 Polypeptide |
| 05/29/2001 | US6238660 Interleukin-12 inducer and medical composition |
| 05/29/2001 | US6238426 Real-time monitoring of photodynamic therapy over an extended time |
| 05/29/2001 | CA2171638C The semaphorin gene family |
| 05/29/2001 | CA2127530C Metal complexes of water soluble texaphyrins |
| 05/29/2001 | CA2064915C Tumour necrosis factor binding ligands |
| 05/25/2001 | WO2001036977A2 Identification of disease markers involving mass-based-separation |
| 05/25/2001 | WO2001036686A2 Genomic polymorphism for predicting therapeutic response |